REGENXBIO

United States
Barbourmeade, Kentucky, United States, 20850

Company profile

REGENXBIO company profile

REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.

Business identity

Contact email
[email protected]
Phone number
(202) 785-7438
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$50,000+
Founded
2009-01-01, Year

Headquarters

Postal code
20850
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
12
Total equity funding
$767.7M
Last funding
Post IPO Debt / $150M / 2025-05-19
Last equity funding
Post IPO Equity / $140M
Investors
19
Lead investors
3
Founders
3
Articles
298
Exited on
2015-09-08

Founders and investors

Founders

James BrownJames M. WilsonKenneth T. Mills

Lead investors

Brookside CapitalVenrockVivo Capital

Investors

Cormorant Asset ManagementForesite CapitalRTW InvestmentsVenrockVivo Capital